| Dr Oscar William Nevarez-pomales, MD | |
|
Zona Industrial Victor Rojas 2, Carr 129, Arecibo, PR 00613-0000 | |
| (787) 385-5320 | |
| Not Available |
| Full Name | Dr Oscar William Nevarez-pomales |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 10 Years |
| Location | Zona Industrial Victor Rojas 2, Arecibo, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629496534 | NPI | - | NPPES |
| 19377 | Other | PR | PUERTO RICO MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 19377 (Puerto Rico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Admin De Servicios Medicos Puerto Ric | San juan, PR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Recinto De Ciencias Medicas | 3678469962 | 192 |
News Archive
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).
Geron Corporation today announced the company's plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.
Arrayit Corporation announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million.
› Verified 8 days ago
| Entity Name | Recinto De Ciencias Medicas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295760676 PECOS PAC ID: 3678469962 Enrollment ID: O20040729001073 |
News Archive
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).
Geron Corporation today announced the company's plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.
Arrayit Corporation announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Oscar William Nevarez-pomales, MD 23 Calle Emilia, Guaynabo, PR 00966-3956 Ph: () - | Dr Oscar William Nevarez-pomales, MD Zona Industrial Victor Rojas 2, Carr 129, Arecibo, PR 00613-0000 Ph: (787) 385-5320 |
News Archive
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).
Geron Corporation today announced the company's plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.
Arrayit Corporation announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million.
› Verified 8 days ago
Dr. Hiram Antonio Ruiz, MD Dermatology Medicare: Medicare Enrolled Practice Location: Cayetano Coll Y Toste Suite 103, Arecibo, PR 00612 Phone: 787-878-4849 Fax: 787-878-7760 |